Adenosine Scalp Lotion for Women: Thickness Is Not Hair Density

A serum promising thicker hair can leave an important question unanswered: does it make existing shafts thicker, increase the number of hairs in a measured area, or improve how the scalp looks in photographs?

Adenosine research measures those outcomes separately. Before paying for a bottle, check which result the seller is claiming and which result its study actually measured.

The women’s trial lasted a year

The pilot trial enrolled 30 Japanese women with diagnosed female pattern hair loss. They applied approximately 3 mL of 0.75% adenosine lotion or placebo twice daily for 12 months. Twenty-seven completed the efficacy assessment.¹

At month 12, dermatologists rated 11 of 13 adenosine users and 5 of 14 placebo users as improved or slightly improved. This primary outcome favored adenosine significantly. It combined small and larger improvements; it was not a count of women whose thinning disappeared.¹

Microscopic measurements found a favorable difference in the proportion of thick hairs, defined as shafts over 80 micrometers in diameter. The placebo group’s thick-hair proportion declined. Growth speed of actively growing hairs also favored adenosine. Hair density, the proportion of growing hairs and the proportion of thin hairs did not differ significantly between groups.¹

No adverse events were diagnosed in the safety assessment. Several authors worked at Shiseido Research Center. The small sample and single population limit what the findings establish.¹

Why “thicker” needs a measurement

These outcomes answer different questions:

Measurement	Question it answers
Hair density	How many shafts are counted per unit of scalp?
Thick-hair proportion	What share of counted shafts exceeds a specified diameter?
Growth speed	How much length do growing hairs gain per day?
Appearance rating	Does an examiner judge the visible thinning to have improved?

A higher thick-hair proportion does not, by itself, establish an increase in the number of hairs. Faster growth does not establish that a greater proportion of follicles is growing. A photograph rating cannot tell you which microscopic change produced the appearance.

That is why a claim such as “more hair” needs its own result, even when an appearance assessment favors the product.

The later pooled results were inconclusive

A systematic review published in 2025 identified seven trials involving 466 participants. They covered different hair-loss diagnoses, men and women, and several formulations. Four tested adenosine as the sole active ingredient; three tested combinations. This total is not 466 women testing the same serum.²

The reviewers pooled six-month measurements from three trials of 0.75% lotion. Two used an inactive matching lotion; the third used niacinamide, which the reviewers treated as inactive for hair growth. The analysis included men as well as the earlier women’s trial. None of the pooled density, thick-hair or thin-hair results was statistically significant.²

For the thick-hair outcome, the reported estimate was an odds ratio of 1.40, with a 95% confidence interval of 0.82 to 2.38. The interval includes 1, the no-difference value. It does not support a precise promise of benefit. Small studies and weaknesses in trial design limited the overall evidence.²

The year-long appearance result and the six-month pooled measurements should both accompany a claim about this ingredient. Choosing only the favorable result would conceal information a buyer needs.

Check the bottle against the study

A leave-on lotion and a rinse-off shampoo have different instructions and exposure times. Adding several ingredients also prevents a study from identifying how much benefit belongs to adenosine alone. The review included both kinds of preparation and combination products.²

Before treating a product page as evidence for your purchase, ask:

• Is the cited trial about this finished formula, or about an ingredient in another preparation?
• Does the concentration match, and is it applied in the same way?
• Did the study measure density, shaft diameter, appearance or satisfaction?
• Were the participants women with the same diagnosis as yours?
• Is the advertised timeframe supported by the trial’s follow-up?

The trial’s application schedule is a research detail, not an instruction to copy with a different bottle. A product without a disclosed concentration or matching study cannot inherit the tested lotion’s result simply by listing adenosine.

Put diagnosis before a serum trial

The AAD³ advises seeing a dermatologist to identify the cause of thinning because several conditions can resemble female pattern hair loss. Its guidance identifies topical minoxidil as the most recommended treatment for that diagnosis and notes U.S. approval of 2% and 5% products for women.³

Minoxidil also has treatment-specific limits, including avoidance during pregnancy, when planning pregnancy and while breastfeeding. Our five decisions before starting topical minoxidil covers that established option in more detail.³

Bring the adenosine product and its cited paper to the same discussion. Ask what would count as a worthwhile change, how you would document it, and whether trying the product would delay a treatment your clinician recommends.

Chapter 8, “The Widening Part,” in Hair, Everywhere explains study-design labels and the difference between established treatments and options still being tested. Those distinctions are useful when a bottle’s promise is broader than its measurements.